Fox Chase Cancer Center | Strategic Alliance Partners

March 03, 2023

John Karanicolas, PhD, co-leader of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, was recently awarded a $1 million grant from the W.M. Keck Foundation to develop a platform that could assist in the development of new drugs.

February 17, 2023

Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology 2023 Junior Faculty Scholar Award in basic/translational research.

February 14, 2023

Researchers at Fox Chase Cancer Center were recently awarded a $550,000 grant from Stand Up To Cancer (SU2C) to fund a new project, “Accelerating and Diversifying Access to Clinical Trials.”

February 06, 2023

Fox Chase Cancer Center physicians Hossein Borghaei, DO, MS, and Elizabeth Plimack, MD, MS, have been named to the 2022 list of Highly Cited Researchers by Clarivate.

February 03, 2023

To synthesize advancements in the detection, treatment, and prevention of kidney cancer and summarize their effects globally, Fox Chase Cancer Center Urologic Oncology Fellow Laura Bukavina, MD, MPH, spearheaded a recent review on the topic.

January 19, 2023

The Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center are pleased to announce the hiring of Lucia Borriello, PhD, as an assistant professor in the Department of Cancer and Cellular Biology at Temple.

January 13, 2023

Fox Chase Cancer Center is pleased to announce the hiring of Lindsey B. Taylor, MD, as an assistant professor in the Department of Hematology/Oncology and the Breast Cancer and Hematology Programs.

January 06, 2023

Joining a list of over 100 previous orators, Robert Uzzo, MD, MBA, FACS, president and CEO of Fox Chase Cancer Center, delivered the Rhoads Oration for the Philadelphia Academy of Surgery this month at The College of Physicians of Philadelphia.

December 19, 2022

Billy Truong, a doctoral candidate at Fox Chase Cancer Center, was awarded the American Society of Hematology Abstract Achievement Award for a poster that he presented at the 64th ASH Annual Meeting and Exposition.

December 07, 2022

A study published by researchers at Fox Chase Cancer Center suggests that race itself may predict disparate outcomes between patients with head and neck cancer.

December 02, 2022

It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.

November 29, 2022

Two Fox Chase Cancer Center researchers have received $75,000 grants from the Kidney Cancer Association to pursue studies that could improve kidney cancer treatment and care.

November 09, 2022

Robert Uzzo, MD, MBA, FACS, has been formally named president and chief executive officer of Fox Chase Cancer Center following a period of interim leadership.

October 19, 2022

Fox Chase Cancer Center is pleased to announce the hiring of Charnita Zeigler-Johnson, PhD, MPH, as Associate Director of Community Outreach and Engagement.

September 30, 2022

Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, was recently awarded the Merton Bernfield Memorial Award from the American Society for Cell Biology, making her one of 18 scientists from across the country to be recognized for their achievements in the life sciences.

September 26, 2022

Fox Chase Cancer Center is pleased to announce the hiring of Anthony M. Villano, MD, as a clinical instructor in the Department of Surgical Oncology.

September 13, 2022

In a recent study, researchers at Fox Chase Cancer Center demonstrated how cancer cells can survive in the body even when faced with a lack of sufficient nutrition, a finding that could be used as a potential indicator of disease status in the organs of pancreatic cancer patients.

September 02, 2022

Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.

August 29, 2022

Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.

July 29, 2022

With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.